BEBT 507
Alternative Names: BEBT-507Latest Information Update: 28 Mar 2025
At a glance
- Originator BeBetter Med
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference; TMPRSS6 protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haemochromatosis; Polycythaemia vera
Most Recent Events
- 04 Mar 2025 Phase-I clinical trials in Haemochromatosis in China (Parenteral) before March 2025 (BeBetter Med pipeline, March 2025)
- 04 Mar 2025 Phase-I clinical trials in Polycythaemia vera in China (Parenteral) before March 2025 (BeBetter Med pipeline, March 2025)
- 30 Sep 2024 Preclinical trials in Haemochromatosis in China (Parenteral) before September 2024 (BeBetter Med pipeline, March 2025)